OBJECTIVE To assess in a phase 3a trial the efficacy of solifenacin succinate, a once-daily oral antimuscarinic agent in development at 5-mg and 10-mg dosage strengths, for the treatment of overactive bladder (OAB) (Yamanouchi Pharmaceutical Co. Ltd, Tokyo, Japan) compared with placebo in patients with symptoms of OAB, i.e. urgency, incontinence, and frequency, with additional objectives being ...

INTRODUCTION Overactive bladder (OAB) is a common condition, especially in middle aged women, requiring long term therapy with anticholinergics to maintain symptoms relief. The aim of the study was to determine the effect of tolterodine extended release (ER) used for OAB treatment on the sexual function of women. MATERIALS AND METHODS Between August 2010 and August 2014, 220 women with confir...

The in vivo muscarinic receptor binding of antimuscarinic agents (oxybutynin, solifenacin, tolterodine, and imidafenacin) used to treat urinary dysfunction in patients with overactive bladder is reviewed. Transdermal administration of oxybutynin in rats leads to significant binding of muscarinic receptors in the bladder without long-term binding in the submaxillary gland and the abolishment of ...

Ligand selectivity of tartrate vs nicotinamide in a water-methanol system has been observed the crystallization Mn(II) and Cd(II) complexes. These complexes were crystallized at room temperature by layered solution technique using mixture solvent M(II):tartrate:nicotinamide (M = Mn, Cd) molar ratio 1:1:2. Complexes M(II)-nicotinamide M(II)-tartrate also prepared for data comparison. Analysis cr...

OBJECTIVE To evaluate the efficacy and side effects of Oxybutinin in comparison to tolterodine in treatment of overactive bladder (OAB) with detrussor overactivity (DOA) in Iranian women. MATERIALS AND METHODS One hundred Iranian old women with clinical symptoms of OAB who show IDO in the filling cystometry participated in this randomized double-blinded parallel-group by using two kinds of th...

AIM To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms. MATERIALS AND METHODS Fifty-two patients (33 men and 19 women; mean age 52.0 years) who underwent insertion of a Double-J stent after urological surgery were prospectively randomized into three groups. Group 1 included 20 patients who receive...

OBJECTIVES To investigate the effects of various muscarinic acetylcholine receptor (mAChR) antagonists, including selective M2 and M3 mAChR antagonists, on bladder overactivity. It has been proposed that the urothelium modulates the activity of bladder afferent pathways. However, the differential roles of mAChR subtypes in local bladder afferent activation remain unclear. METHODS Cystometry w...

Fesoterodine extended-release (brand name Toviaz) is a new competitive muscarinic receptor antagonist labeled for the treatment of overactive bladder (OAB). Here we have undertaken a substantial update to a systematic review evaluating the effects of fesoterodine in the treatment of OAB. Our results indicate that fesoterodine was found to have significant improvements in the management of OAB s...